Nivolumab in advanced lung cancer: Indication of major added benefit
Patients with advanced nonsquamous NSCLC who have already undergone chemotherapy survive longer with the drug Nivolumab than with docetaxel.
Source: ScienceDaily Headlines - Category: Science Source Type: news
More News: Cancer | Cancer & Oncology | Chemotherapy | Docetaxel | Lung Cancer | Non-Small Cell Lung Cancer | Science | Taxotere